Nasal application of a gel formulation of N‐acetyl‐aspartyl glutamic acid (NAAGA) compared with placebo and disodium cromoglycate in the symptomatic treatment of pollinosis*

Abstract

A gel formulation of the antiallergic compound N-acetyl-aspartyl glutamic acid (NAAGA) (Rhinaaxia (R)) has been evaluated in a multicenter, randomized, double-blind, three-arm, parallel-group comparison with placebo gel (P) and disodium cromoglycate (DSCG) in outpatients suffering from seasonal allergic rhinitis (pollinosis). Nose and eye symptoms were assessed daily by the patients on visual analog scales (VAS), and medical examinations were held after 1 week and at the end of the 4-week treatment. The use of rescue medications (H1-antagonist (terfenadine) and soothing eye-drops (Spersallerg) was recorded as a main assessment indicator of efficacy. For the efficacy analysis, only the periods with relevant pollen concentrations (> or = 50 grains/m3) were considered. The study extended over the two pollen seasons 1989 and 1990. Of 230 included patients, 190 were suitable for efficacy analysis (R = 63, P = 64, DSCG = 63). The VAS data did not reveal a difference between the treatment groups for nasal symptoms, whereas the use of terfenadine tablets was significantly lower in the Rhinaaxia group than in either the placebo (P = 0.0001) or DSCG group (P = 0.03). The eye symptoms were significantly less severe in the Rhinaaxia group than in both placebo (P = 0.0001) and DSCG (P < 0.01) groups. In addition, the use of rescue medication was significantly higher in the placebo than in the Rhinaaxia treatment group (P = 0.0001). The incidence of local untoward effects (itching/burning sensation in the nose) was slightly higher in the Rhinaaxia group, while the overall tolerability assessment was similarly good in all three treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Vibrational spectroscopy and DFT calculations of di‐amino acid peptides: α‐ and β‐N‐acetyl‐L‐Asp‐L‐Glu in the solid state

“…α-N-acetyl-L-Asp-L-Glu is used as an anti-allergic medication in eye drops and nasal preparations. [27] α-N-acetyl-L-Asp-L-Glu is catabolized to N-acetyl-L-aspartic acid and potentially exitotoxic neurotransmitter by the enzyme glutamate carboxypeptidase II (GCP II), also known as N-acetylated-α-linked acidic dipeptidase (NAALADase), in both normal and patho-physiological conditions of the neurological systems. [28] It is a highly selective agonist for type 3 metabotropic glutamate receptors (mGluR3) and can inhibit L-Glu release [29] (which is released in the brain upon stress and can lead to depression).…”

Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA

“…NAAGA is a naturally occurring dipeptide in mammalian brain 11. A mast cell degranulation inhibitor, which also inhibits complement activation and leukotriene release,12 it had been shown to be similar in efficacy to cromolyn sodium in the symptomatic treatment of seasonal allergic rhinitis13 and to modulate allergen induced nasal symptoms and mediator release 14. Although it has been reported to be ineffective in giant papillary conjunctivitis,15 a study in allergic conjunctivitis showed it be as effective as cromolyn sodium 16…”